What is hydrangenol and what does it do in the body?

Hydrangenol (HG) is a dihydroisocoumarin compound found at 192 ± 3 mg/100 g in Hydrangea macrophylla leaves that inhibits the carbohydrate-digesting enzymes α-glucosidase (IC50 0.97 mg/mL) and α-amylase (IC50 3.6 mg/mL) in vitro, potentially slowing sugar absorption. It also demonstrates antioxidant activity by scavenging ABTS•+ radicals, with ORAC values of 16.5–27.0 mmol TE/mmol, though these effects have not yet been confirmed in human clinical studies.

Is hortensia (Hydrangea macrophylla) safe to consume?

No formal human safety studies have been conducted on Hydrangea macrophylla leaf extracts or isolated compounds, so no established safe dose exists for supplemental use. Traditional fermented amacha tea from subsp. serrata has a long history of ceremonial consumption in Japan without documented widespread adverse events, but non-fermented or high-concentration preparations carry unquantified risk, and the plant contains cyanogenic compounds in some species, making medical supervision advisable.

How does hortensia compare to acarbose for blood sugar management?

In vitro, hydrangenol from Hydrangea macrophylla inhibits α-glucosidase with an IC50 of 0.97 mg/mL—more potently than the pharmaceutical drug acarbose at IC50 2.1 mg/mL under the same assay conditions—while compound 12 from H. macrophylla var. acuminata achieves IC50 3.4 ± 0.2 µM. However, these are cell-free biochemical assays; no human pharmacokinetic or clinical trial data exist, so direct therapeutic comparison to acarbose in patients is not currently possible.

What is phyllodulcin and why is it used as a natural sweetener?

Phyllodulcin (PD) is a dihydroisocoumarin present at 37 ± 3 mg/100 g in H. macrophylla leaves, with higher concentrations in young fermented leaves of the tea-hortensia subspecies serrata, and it acts as a potent sweetness enhancer by allosterically potentiating the T1R2/T1R3 sweet taste receptor. Unlike sugar, phyllodulcin contributes negligible caloric load, which is why fermented young leaves of H. macrophylla subsp. serrata have been used in Japan for centuries to produce amacha, a naturally sweet herbal tea.

Are there any clinical trials on Hydrangea macrophylla leaf extract?

As of the available research record, no peer-reviewed human clinical trials have been published on Hydrangea macrophylla leaf extracts, hydrangenol, phyllodulcin, or any isolated Hydrangea compound for any health indication. All quantitative efficacy data derive from in vitro enzyme inhibition assays and antioxidant measurements; transitional animal pharmacology studies and human pharmacokinetic investigations are needed before clinical benefit can be established.

What is the difference between Hydrangea macrophylla and Hydrangea macrophylla subsp. serrata for blood sugar support?

Both subspecies contain similar bioactive compounds including hydrangenol and phyllodulcin, but H. macrophylla subsp. serrata (also called Hydrangea serrata) is traditionally used in Japanese herbalism and may have slightly different phytochemical profiles depending on cultivation conditions. Research on α-glucosidase inhibition has primarily focused on H. macrophylla leaf extracts, making this the more clinically studied form for glycemic support. The subspecies distinction is largely botanical; supplemental efficacy likely depends more on extraction method and compound standardization than on subspecies selection alone.

Why is hortensia less commonly available in supplements compared to other blood sugar herbs?

Hortensia (Hydrangea) has limited commercial cultivation for supplement use compared to established ingredients like bitter melon or fenugreek, and regulatory status varies by region—it is more established in traditional Japanese and Chinese medicine than in Western herbal markets. Additionally, standardization of active compounds like hydrangenol and phyllodulcin presents manufacturing challenges, and the ingredient requires more research validation to meet quality standards for mass-market supplement development. Supply chain development and increased clinical evidence would likely expand its commercial availability in Western markets.

Can hortensia leaf extract be standardized for consistent potency, and how would I know if a supplement is properly standardized?

Quality hortensia supplements should be standardized to hydrangenol content (the most potent α-glucosidase inhibitor) or to total polyphenol/flavonoid content, though standardization protocols for this ingredient are still emerging compared to mainstream botanicals. Look for supplements that clearly state the percentage or milligrams of standardized extract (e.g., "H. macrophylla leaf extract standardized to 10% hydrangenol") and third-party testing verification. Without standardization specifications on the label, the actual bioactive compound concentration and efficacy cannot be reliably predicted.

Hortensia

Hortensia leaves contain the dihydroisocoumarins hydrangenol (HG) and phyllodulcin (PD), alongside bis-iridoid glycosides and diverse phenolics, which exert antioxidant activity through radical scavenging and modulate carbohydrate-metabolizing enzymes via competitive inhibition. In vitro, hydrangenol inhibits α-glucosidase with an IC50 of 0.97 mg/mL—outperforming the pharmaceutical comparator acarbose (IC50 2.1 mg/mL)—and suppresses polyphenol oxidase activity by up to 61% at 1–2 mg/mL, though no human clinical trial data yet validate these effects.

Category: Pacific Islands Evidence: 1/10 Tier: Preliminary

Origin & History

Hydrangea macrophylla and its subspecies are native to coastal regions of Japan and China, thriving in temperate, humid climates with well-drained, moderately acidic soils and partial shade. The tea-hortensia subspecies serrata has been cultivated in Japan for centuries, particularly in mountainous areas of Shikoku and Kyushu, where leaves are harvested for traditional herbal preparations. Pacific Island adaptations of Hydrangea species draw on broader Polynesian and Melanesian ethnobotanical traditions, where blended multi-herb preparations incorporating hortensia have been used for general wellness and specific ailments.

Historical & Cultural Context

Hydrangea macrophylla subsp. serrata has been used in Japan for over a millennium in the preparation of amacha (sweet tea), a fermented leaf beverage consumed ceremonially during the Buddhist festival of Hana Matsuri commemorating the birth of Siddhartha Gautama, where it is traditionally poured over statues of the infant Buddha. The sweetness of amacha, attributable to phyllodulcin accumulation in fermented young leaves, was recognized in pre-scientific Japanese folk medicine as a health-promoting property distinct from sugar-derived sweetness, and the preparation was also used as a general tonic and for skin conditions in some regional traditions. In Pacific Island ethnobotanical contexts, Hydrangea species or closely related ornamental introductions have been incorporated into multi-herb blended preparations used for a range of ailments, reflecting the region's adaptive integration of introduced plant species into existing traditional healing frameworks, though specific documented formulations remain poorly recorded in the scientific literature. The modern scientific interest in hydrangenol and phyllodulcin as bioactive leads for metabolic disease and natural sweetener development represents a convergence of traditional-use knowledge and contemporary drug discovery methodology.

Health Benefits

- **α-Glucosidase Inhibition (Glycemic Modulation)**: Hydrangenol (HG) inhibits α-glucosidase at an IC50 of 0.97 mg/mL in vitro, surpassing acarbose's IC50 of 2.1 mg/mL, suggesting a potential mechanism for slowing postprandial glucose absorption; isolated compound 12 from H. macrophylla var. acuminata demonstrated an even more potent IC50 of 3.4 ± 0.2 µM against the same enzyme.
- **α-Amylase Inhibition**: HG extracts inhibit salivary and pancreatic α-amylase by approximately 52% at an IC50 of 3.6 mg/mL, compared with 99% inhibition by acarbose at 0.51 mg/mL; this dual carbohydrase inhibition profile, if translatable in vivo, could contribute to blunted starch digestion and reduced glycemic load.
- **Antioxidant Activity**: Total phenolic content ranging from 7.1 to 11.2 g GAE/100 g of leaf extract confers strong radical-scavenging capacity, quantified as TEAC 1.8–3.2 mmol TE/mmol and ORAC 16.5–27.0 mmol TE/mmol, with HG reducing ABTS•+ radicals in a concentration-dependent manner monitored spectrophotometrically at 730 nm.
- **PTP1B Inhibition (Insulin Signaling Pathway)**: Compound 12 isolated from H. macrophylla var. acuminata inhibits protein tyrosine phosphatase 1B (PTP1B) at 8.0 ± 1.1 µM in vitro; PTP1B is a validated molecular target for insulin and leptin sensitization, making this finding mechanistically relevant to metabolic health, pending in vivo confirmation.
- **Polyphenol Oxidase (PPO) Suppression**: HG suppresses PPO activity by 61% at concentrations of 1–2 mg/mL, with activity decreasing to 46% inhibition at a higher 4 mg/mL dose, indicating a non-linear, potentially biphasic dose-response; PPO inhibition has implications for controlling oxidative browning and may reflect broader anti-inflammatory enzyme modulation.
- **Taste Modification and Palatability Enhancement**: Phyllodulcin (PD), present at 37 ± 3 mg/100 g in H. macrophylla leaves and at higher concentrations in young leaves of subsp. serrata cultivars, acts as a potent sweetness-enhancing taste modifier without caloric contribution, supporting its historical use in sweet tea preparations and its potential as a natural flavor adjunct.
- **Diverse Secondary Metabolite Activity**: The 41 secondary metabolites characterized from H. macrophylla var. acuminata, including novel phenolics (e.g., compound 3, C20H26O7) and bis-iridoid glycosides (compounds 30–32, up to C34H50O19 at 1–100 µM), provide a broad bioactive scaffold; molecular docking of compounds 8, 9, and 12 against glucosidase and PTP1B active sites suggests multiple simultaneous pharmacological targets within a single extract.

How It Works

Hydrangenol and related dihydroisocoumarins competitively inhibit intestinal α-glucosidase and α-amylase by occupying substrate-binding pockets within the enzyme active sites, a mechanism supported by molecular docking analyses showing favorable binding geometries for compound 12 (IC50 3.4 ± 0.2 µM vs. α-glucosidase) and compound 8 (IC50 21.9 ± 0.4 µM), thereby slowing oligosaccharide cleavage and glucose liberation at the brush border. Compound 12 concurrently inhibits PTP1B at 8.0 ± 1.1 µM through direct interaction with the enzyme's catalytic cysteine-containing phosphatase domain, which normally dephosphorylates the insulin receptor tyrosine kinase and attenuates downstream PI3K/Akt insulin signaling; its inhibition prolongs receptor phosphorylation and theoretically enhances insulin sensitivity. The high total phenolic load (up to 11 ± 0.7 g GAE/100 g) contributes antioxidant activity through electron donation to ABTS•+ and peroxyl radicals, quantified via TEAC and ORAC assays, reducing oxidative stress that would otherwise accelerate endothelial and metabolic dysfunction. Phyllodulcin modulates gustatory receptor signaling at the T1R2/T1R3 heterodimeric sweet taste receptor complex, acting as an allosteric potentiator rather than a direct agonist, which amplifies perceived sweetness without triggering insulin secretion pathways associated with caloric sugars.

Scientific Research

All available evidence for Hydrangea spp. bioactivity is derived exclusively from in vitro biochemical assays and phytochemical characterization studies; no peer-reviewed human randomized controlled trials, observational cohort studies, or even animal pharmacodynamic studies were identified in the available research base. The most rigorous in vitro work quantified enzyme inhibition kinetics (IC50 values for α-glucosidase, α-amylase, and PTP1B) and antioxidant metrics (TEAC, ORAC) using isolated leaf extracts and purified compounds tested at 1–100 µM or 1–4 mg/mL, providing mechanistically plausible but clinically unvalidated findings. Phytochemical profiling of H. macrophylla var. acuminata identified 41 secondary metabolites including novel phenolics and bis-iridoid glycosides via HPLC and NMR, with molecular docking supporting binding hypotheses for compounds 8, 9, and 12, though docking scores do not substitute for experimental pharmacological or clinical confirmation. The collective evidence base therefore remains at a preclinical, exploratory stage, and extrapolation of in vitro IC50 values to effective human doses requires substantial additional pharmacokinetic, bioavailability, and clinical investigation.

Clinical Summary

No human clinical trials have been conducted on Hydrangea macrophylla leaf extracts, hydrangenol, phyllodulcin, or any isolated compound from Hydrangea spp. for any health indication as of the available research record. Consequently, there are no reportable effect sizes, confidence intervals, adverse event profiles from controlled exposure, or regulatory-grade efficacy conclusions derived from human subjects. The sole quantitative bioactivity data originate from in vitro enzyme inhibition experiments and radical-scavenging assays, which provide hypothesis-generating mechanistic insights but cannot be used to draw conclusions about clinical benefit, optimal dosing, or therapeutic equivalency in humans. Until well-designed Phase I pharmacokinetic studies and subsequent efficacy trials are completed, the clinical utility of hortensia-derived preparations remains speculative, regardless of the biochemical plausibility suggested by the in vitro data.

Nutritional Profile

Hydrangea macrophylla leaves are characterized primarily by their secondary metabolite content rather than conventional macronutrient density: hydrangenol is present at 192 ± 3 mg/100 g dry leaf weight and phyllodulcin at 37 ± 3 mg/100 g, both as dihydroisocoumarin-class phenolics. Total phenolic content measured by Folin-Ciocalteu ranges from 7.1 to 11.2 g gallic acid equivalents (GAE)/100 g, among the higher values reported for edible plant leaves, with the highest concentration (11 ± 0.7 g GAE/100 g) observed in optimally diluted methanol-water extracts. An additional 41 characterized secondary metabolites from H. macrophylla var. acuminata include novel phenolic acids, flavonoid derivatives, and bis-iridoid glycosides (molecular weights up to C34H50O19), contributing to the broad phytochemical complexity. Conventional macronutrient data (protein, fat, carbohydrate, fiber fractions), mineral content, and vitamin profiles for Hydrangea leaves are not documented in the available phytochemical literature, and bioavailability of the key dihydroisocoumarins following oral ingestion—including first-pass metabolism, plasma half-life, and tissue distribution—has not been determined in any published pharmacokinetic study.

Preparation & Dosage

- **Traditional Leaf Tea (Amacha)**: Young leaves of H. macrophylla subsp. serrata are fermented, dried, and brewed as a sweet herbal tea in Japanese tradition; no standardized dose has been established, but historical practice involves infusions of approximately 2–5 g dried leaf per 200 mL hot water.
- **Methanol/Water Leaf Extract (Research Grade)**: Laboratory studies employ 1:1 (v/v) methanol-water extraction of dried powdered leaves, with bioactive concentrations tested at 1–4 mg/mL for enzyme inhibition assays; direct translation to supplement dosing is not validated.
- **Isolated Hydrangenol (HG)**: Research uses indicate effective concentrations of approximately 0.97 mg/mL for α-glucosidase inhibition (IC50) and 3.6 mg/mL for α-amylase inhibition in vitro; no human oral dose equivalents have been established or tested.
- **Isolated Compound 12 and Novel Phenolics**: In vitro bioactivity observed at 3.4–43.8 µM ranges for glucosidase inhibition and 8.0 µM for PTP1B inhibition; these micromolar concentrations have no corresponding validated oral dosing regimen.
- **Standardization**: No commercial standardization to hydrangenol, phyllodulcin, or total phenolics percentage exists in recognized pharmacopeial or regulatory frameworks; VIS-NIR spectroscopic modeling has been proposed for quality estimation in cultivation but is not applied in commercial products.
- **Timing and Formulation Notes**: Traditional amacha consumption occurs seasonally (e.g., during Hana Matsuri festival in Japan on April 8); no timing guidance relevant to clinical outcomes (e.g., pre-meal for glycemic effects) has been empirically tested.

Synergy & Pairings

The co-presence of hydrangenol and phyllodulcin within a single leaf extract creates a potential within-ingredient synergy: hydrangenol provides enzyme-inhibitory and antioxidant activity while phyllodulcin modulates sweet taste receptor signaling, together supporting palatability of low-sugar dietary strategies alongside carbohydrase inhibition, though this combination has not been tested in vivo. Theoretically, pairing Hydrangea leaf extracts with other characterized α-glucosidase inhibitors of plant origin—such as mulberry leaf (1-deoxynojirimycin) or bitter melon (charantin)—could produce additive or synergistic glycemic modulation via complementary active-site binding modes, as suggested by the distinct structural scaffolds of compound 12 versus iminosugar inhibitors. The high total phenolic content of Hydrangea leaf may also synergize with vitamin C or other hydrophilic antioxidants to regenerate oxidized phenolic radicals and extend the effective antioxidant duration, a mechanism well-established for polyphenol-rich matrices, though specific Hydrangea-vitamin C co-supplementation has not been studied.

Safety & Interactions

No systematic human safety data, clinical toxicology studies, or pharmacovigilance reports for Hydrangea macrophylla leaf extracts or isolated compounds exist in the available literature, and therefore no established maximum tolerated dose, no-observed-adverse-effect level (NOAEL), or acceptable daily intake has been defined for any human population. The in vitro inhibition of α-amylase and α-glucosidase at milligram-per-milliliter concentrations raises a theoretical concern for additive hypoglycemic effects if consumed concurrently with antidiabetic medications such as acarbose, metformin, sulfonylureas, or insulin, warranting caution pending pharmacokinetic data. The non-linear dose-response observed for polyphenol oxidase inhibition—61% suppression at 1–2 mg/mL decreasing to 46% at 4 mg/mL—suggests possible dose-dependent pharmacodynamic complexity that has not been characterized in living systems, and higher-dose preparations should be approached with caution. Pregnancy, lactation, and pediatric safety have not been studied; all Hydrangea plant parts contain cyanogenic glycosides (reported in some species), and ingestion of non-traditional or non-fermented preparations carries unquantified risk, making medical supervision advisable for any therapeutic use beyond traditional amacha tea consumption.